So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Circ Cardiovasc Genet. 2015 Dec;8(6):749-51. doi: 10.1161/CIRCGENETICS.115.001256.

¹ From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
² From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Zahid.ahmad@utsouthwestern.edu.

No abstract available

Keywords: Editorials; LDLR; PCSK9; cardiovascular disease; hypercholesterolemia; lipoprotein; pharmacology; treatment.

Publication types